IL135590A - Process for the reduction of oxiranyl epothilones to olefinic epothilones - Google Patents

Process for the reduction of oxiranyl epothilones to olefinic epothilones

Info

Publication number
IL135590A
IL135590A IL13559098A IL13559098A IL135590A IL 135590 A IL135590 A IL 135590A IL 13559098 A IL13559098 A IL 13559098A IL 13559098 A IL13559098 A IL 13559098A IL 135590 A IL135590 A IL 135590A
Authority
IL
Israel
Prior art keywords
epothilones
reduction
oxiranyl
olefinic
relates
Prior art date
Application number
IL13559098A
Other languages
English (en)
Other versions
IL135590A0 (en
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL135590A0 publication Critical patent/IL135590A0/xx
Publication of IL135590A publication Critical patent/IL135590A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13559098A 1997-12-04 1998-12-01 Process for the reduction of oxiranyl epothilones to olefinic epothilones IL135590A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6754997P 1997-12-04 1997-12-04
US8256398P 1998-04-21 1998-04-21
PCT/US1998/025464 WO1999028324A1 (fr) 1997-12-04 1998-12-01 Procede de reduction d'epothilones d'oxiranyle en epothilones olefiniques

Publications (2)

Publication Number Publication Date
IL135590A0 IL135590A0 (en) 2001-05-20
IL135590A true IL135590A (en) 2003-09-17

Family

ID=26748002

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13559098A IL135590A (en) 1997-12-04 1998-12-01 Process for the reduction of oxiranyl epothilones to olefinic epothilones

Country Status (13)

Country Link
EP (1) EP1042327B1 (fr)
JP (1) JP4434484B2 (fr)
KR (1) KR100574454B1 (fr)
AT (1) ATE250066T1 (fr)
AU (1) AU738576B2 (fr)
CA (1) CA2311929A1 (fr)
DE (1) DE69818304T2 (fr)
ES (1) ES2207015T3 (fr)
HK (1) HK1028401A1 (fr)
HU (1) HUP0100582A3 (fr)
IL (1) IL135590A (fr)
TW (1) TWI221469B (fr)
WO (1) WO1999028324A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (fr) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthèse d'épitholones, intermédiaires, analogues et leur utilisation
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6320045B1 (en) * 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
MXPA00008365A (es) * 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
EP2308833A3 (fr) 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Inhibiteurs de kinase de tyrosine de protéine cyclique
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP2266607A3 (fr) 1999-10-01 2011-04-20 Immunogen, Inc. Des immunoconjugués pour le traitement des cancers.
EP1340498A1 (fr) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Utilisation d'épothilones dans le traitement de maladies du cerveau associées aux processus de prolifération
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
EP1575556A2 (fr) * 2002-05-20 2005-09-21 Kosan Biosciences, Inc. Methodes d'administration d'epothilone d
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004045518A2 (fr) 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Modulateurs lies a prolyl uree a chaine ouverte de la fonction du recepteur d'androgene
EP1559447A1 (fr) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation d'epothilone pour le traitement de defauts de connectivité neuronale comme par exemple la schizophrenie et l'autisme
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
AU2009240538B2 (en) 2008-04-24 2014-08-07 Bristol-Myers Squibb Company Use of Epothilone D in treating Tau-associated diseases including Alzheimer's disease
US8846006B2 (en) 2011-01-20 2014-09-30 Board Of Regents, The University Of Texas System MRI markers, delivery and extraction systems, and methods of manufacture and use thereof
TWI597065B (zh) 2011-06-10 2017-09-01 梅爾莎納醫療公司 蛋白質－聚合物－藥物共軛體
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
WO2014075391A1 (fr) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 Composé du platine et de dérivé de l'acide malonique ayant un groupe partant contenant un groupe amino ou alkylamino
CA2892863C (fr) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Echafaudage polymere fonde sur des filaments helicoidaux apparies (phf) pour l'administration ciblee de medicaments
WO2014093640A1 (fr) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Conjugués hydroxy-polymère-médicament-protéine
WO2014198645A1 (fr) 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose
EP3054992B1 (fr) 2013-10-11 2019-08-14 Asana BioSciences, LLC Conjugués médicament-polymère-protéine
JP6420331B2 (ja) 2013-10-11 2018-11-07 メルサナ セラピューティクス，インコーポレイティド タンパク質−高分子−薬剤コンジュゲート
CN103936748A (zh) * 2014-05-08 2014-07-23 成都摩尔生物医药有限公司 一种埃博霉素b内酰胺衍生物的制备方法
EP3474901A1 (fr) 2016-06-27 2019-05-01 Tagworks Pharmaceuticals B.V. Tétrazine clivable utilisée dans l'activation de médicaments bio-orthogonaux
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018237262A1 (fr) 2017-06-22 2018-12-27 Mersana Therapeutics, Inc. Procédés de production de matrices polymères transportant des médicaments, et conjugués protéine-polymère-médicament
DK3788032T3 (da) 2018-05-04 2024-04-15 Tagworks Pharmaceuticals B V Forbindelser omfattende en linker til øgning af transcyklooctenstabilitet
WO2019212356A1 (fr) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B .V. Tétrazines pour un rendement élevé de conjugaison de chimie click in vivo et un rendement élevé de libération de chimie click
WO2020092385A1 (fr) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Conjugués anticorps-médicament modifiés par une cystéine avec des lieurs contenant des peptides
JP2022537543A (ja) 2019-06-17 2022-08-26 タグワークス ファーマシューティカルス ビー．ブイ． 高速で且つ効率的なクリック放出の為の化合物
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
JP2024532537A (ja) 2021-09-06 2024-09-05 ヴェラクサ バイオテック ゲーエムベーハー 真核生物における遺伝暗号の拡張のための新規アミノアシルｔＲＮＡ合成酵素変異体
EP4186529A1 (fr) 2021-11-25 2023-05-31 Veraxa Biotech GmbH Conjugués anticorps-charge utile améliorés (apcs) préparés par conjugaison spécifique à un site à l'aide d'une expansion de code génétique
WO2023094525A1 (fr) 2021-11-25 2023-06-01 Veraxa Biotech Gmbh Conjugués anticorps-charge utile améliorés (apc) préparés par conjugaison spécifique à un site à l'aide d'une expansion de code génétique
CA3239713A1 (fr) 2021-12-08 2023-06-15 Edward A. LEMKE Charges utiles hydrophiles fonctionnalisees a la tetrazine destinees a la preparation de conjugues de ciblage
EP4372000A3 (fr) 2022-02-15 2024-07-17 Tagworks Pharmaceuticals B.V. Proteine il12 masquee
WO2024013724A1 (fr) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Conjugués anticorps-médicament
WO2024080872A1 (fr) 2022-10-12 2024-04-18 Tagworks Pharmaceuticals B.V. Bicyclononènes contraints
WO2024153789A1 (fr) 2023-01-20 2024-07-25 Basf Se Composition de biopolymère stabilisée, sa fabrication et son utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE59610712D1 (de) * 1995-11-17 2003-10-16 Biotechnolog Forschung Gmbh Epothilonderivate, herstellung und verwendung

Also Published As

Publication number Publication date
DE69818304D1 (de) 2003-10-23
IL135590A0 (en) 2001-05-20
JP2001525324A (ja) 2001-12-11
HUP0100582A3 (en) 2003-03-28
EP1042327B1 (fr) 2003-09-17
HK1028401A1 (en) 2001-02-16
ES2207015T3 (es) 2004-05-16
EP1042327A1 (fr) 2000-10-11
ATE250066T1 (de) 2003-10-15
WO1999028324A1 (fr) 1999-06-10
AU738576B2 (en) 2001-09-20
HUP0100582A2 (hu) 2001-09-28
TWI221469B (en) 2004-10-01
DE69818304T2 (de) 2004-07-01
AU1540899A (en) 1999-06-16
KR100574454B1 (ko) 2006-04-27
CA2311929A1 (fr) 1999-06-10
JP4434484B2 (ja) 2010-03-17
KR20010031976A (ko) 2001-04-16
EP1042327A4 (fr) 2002-07-17

Similar Documents

Publication Publication Date Title
IL135590A (en) Process for the reduction of oxiranyl epothilones to olefinic epothilones
HUP0201467A2 (en) A process for the reduction of oxiranyl epothilones to olefinic epothilones
AU1601100A (en) Improved processes for the synthesis of oligomeric compounds
MX9605206A (es) 1alfa,26-dihidroxi-d-homo-vitamina d3.
BG102788A (en) New methods for the preparation of intermediate compounds for presticides
IL133363A (en) Process for the production of herapin
BG103649A (en) Method for the preparation of eprosartan
BG103650A (en) Method for the preparation of eprosartan
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
HUP0105439A3 (en) Process for the synthesis of hiv protease inhibitors
ZA98898B (en) Process for the production of halogeno-o-hydroxydiphenyl compounds
IL128028A0 (en) Treatment of psychotic disorders
EP0617040A3 (fr) Production d'alkyl phosphites.
ZA989338B (en) Process for the synthesis of chloropurine intermediates.
GB2327420B (en) Process for the production of oxygenated compounds
IL124178A (en) Process for the production of distryryl-biphenyl compounds
HUP9900493A3 (en) General process for the epoxidation of olefinic double bonds
AU2460995A (en) Production of olefins by transhydrogenation
BG102563A (en) Method and intermediate compounds for the production of pesticidal fluorolefinic compounds
AU5477199A (en) Novel process for the synthesis of exochelins
AU6302698A (en) Process for the purification of substituted p-nitrodiphenylethers
AU1063300A (en) Process for the production of trifluoromethyltropanone cyanohydrin
IL136026A0 (en) Process for the production of formylimidazoles
AU7969600A (en) Process for the partial hydrogenation of a nitrile compound containing two or more nitrile groups
SI1066276T1 (en) Process for the synthesis of hiv protease inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees